# Thermo Fisher Scientific (TMO) financials

Thermo Fisher Scientific reported revenue of $44.6 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 3.9% from fiscal 2024. Net income was $6.70 billion and diluted earnings per share $17.74.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 26 Sep 2026), revenue was $12.1 billion, up 9.1% from a year earlier.

Source: Thermo Fisher Scientific's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026. Amounts in USD. Page: https://aapwire.com/stocks/TMO. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

Thermo Fisher Scientific reported revenue of $12.1 billion, up 9.1% from a year earlier, net income of $1.72 billion and diluted earnings per share of $4.64 against $4.27 for the third quarter of fiscal 2026 (the three months to 26 Sep 2026).

From its quarterly report, the results first announced on 21 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $12.14B | $11.12B | +9.1% |
| Gross profit | $5.13B | $4.58B | +12.0% |
| Gross margin | 42.3% | 41.2% | +1.1 pts |
| Operating income | $2.26B | $1.94B | +16.6% |
| Operating margin | 18.6% | 17.5% | +1.2 pts |
| Net income | $1.72B | $1.62B | +6.5% |
| Diluted EPS | $4.64 | $4.27 | +8.7% |
| Operating cash flow | $2.55B | $2.24B | +13.9% |
| Capital expenditure | $437.0M | $404.0M | +8.2% |
| Free cash flow | $2.11B | $1.83B | +15.1% |

Page: https://aapwire.com/stocks/TMO/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $18.27B | $20.92B | $24.36B | $25.54B | $32.22B | $39.21B | $44.91B | $42.86B | $42.88B | $44.56B |
| Revenue growth | +7.7% | +14.5% | +16.4% | +4.9% | +26.1% | +21.7% | +14.5% | −4.6% | +0.1% | +3.9% |
| Gross profit | $10.06B | $11.94B | $10.86B | $11.33B | $16.00B | $19.64B | $18.97B | $17.10B | $17.70B | $18.24B |
| Operating income | $2.46B | $2.96B | $3.78B | $4.59B | $7.79B | $10.03B | $8.39B | $6.86B | $7.34B | $7.75B |
| Net income | $2.02B | $2.23B | $2.94B | $3.70B | $6.38B | $7.72B | $6.95B | $6.00B | $6.33B | $6.70B |
| Diluted EPS | $5.09 | $5.59 | $7.24 | $9.17 | $15.96 | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 |
| Operating cash flow | $3.26B | $4.00B | $4.54B | $4.97B | $8.29B | $9.31B | $9.15B | $8.41B | $8.67B | $7.82B |
| Capital expenditure | $444.0M | $508.0M | $758.0M | $926.0M | $1.47B | $2.52B | $2.24B | $1.48B | $1.40B | $1.52B |
| Free cash flow | $2.81B | $3.50B | $3.79B | $4.05B | $6.82B | $6.79B | $6.91B | $6.93B | $7.27B | $6.29B |
| Gross margin | 55.1% | 57.1% | 44.6% | 44.4% | 49.7% | 50.1% | 42.2% | 39.9% | 41.3% | 40.9% |
| Operating margin | 13.5% | 14.2% | 15.5% | 18.0% | 24.2% | 25.6% | 18.7% | 16.0% | 17.1% | 17.4% |
| Net margin | 11.1% | 10.6% | 12.1% | 14.5% | 19.8% | 19.7% | 15.5% | 14.0% | 14.8% | 15.0% |
| Cash and equivalents | $786.0M | $1.33B | $2.10B | $2.40B | $10.32B | $4.48B | $8.52B | $8.08B | $4.01B | $9.85B |
| Total debt | $16.63B | $21.01B | $18.99B | $18.49B | $22.55B | $36.34B | $36.07B | $36.42B | $32.78B | $40.85B |
| Shareholders' equity | $21.54B | $25.41B | $27.59B | $29.68B | $34.51B | $40.79B | $43.98B | $46.73B | $49.58B | $53.41B |
| Diluted shares | 397M | 398M | 406M | 403M | 399M | 397M | 394M | 388M | 383M | 378M |
| Dividends per share | $0.60 | $0.60 | $0.68 | $0.76 | $0.88 | $1.04 | $1.20 | $1.40 | $1.56 | $1.72 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $11.39B | $10.36B | $10.86B | $11.12B | $12.21B | $11.01B | $11.99B | $12.14B |
| Revenue, year on year | +4.7% | +0.2% | +3.0% | +4.9% | +7.2% | +6.2% | +10.5% | +9.1% |
| Gross margin | 42.3% | 40.9% | 40.6% | 41.2% | 41.0% | 40.3% | 40.7% | 42.3% |
| Operating income | $2.02B | $1.72B | $1.83B | $1.94B | $2.25B | $1.86B | $2.09B | $2.26B |
| Net income | $1.83B | $1.51B | $1.62B | $1.62B | $1.96B | $1.65B | $1.74B | $1.72B |
| Diluted EPS | $4.78 | $3.98 | $4.28 | $4.27 | $5.21 | $4.43 | $4.68 | $4.64 |
| Free cash flow | $2.81B | $361.0M | $1.10B | $1.83B | $2.99B | $816.0M | $1.68B | $2.11B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Organic revenue (change on a year)](https://aapwire.com/stocks/TMO/kpi/organic-revenue-change-on-a-year) | 6% | quarter to 26 Sep 2026 | up 3.0 points |
| [Remaining performance obligations](https://aapwire.com/stocks/TMO/kpi/remaining-performance-obligations) | $29.9B | at 26 Sep 2026 | up 12.9% |
| [Product revenues](https://aapwire.com/stocks/TMO/kpi/product-revenues) | $6.8B | quarter to 26 Sep 2026 | up 4.1% |
| [Service revenues](https://aapwire.com/stocks/TMO/kpi/service-revenues) | $5.4B | quarter to 26 Sep 2026 | up 16.2% |
| [Consumables revenue](https://aapwire.com/stocks/TMO/kpi/consumables-revenue) | $4.9B | quarter to 26 Sep 2026 | up 4.1% |
| [Instruments revenue](https://aapwire.com/stocks/TMO/kpi/instruments-revenue) | $1.9B | quarter to 26 Sep 2026 | up 4.0% |
| [Clinical research revenue](https://aapwire.com/stocks/TMO/kpi/clinical-research-revenue) | $2.4B | quarter to 26 Sep 2026 | up 21.1% |
| [Research and safety market channel revenue](https://aapwire.com/stocks/TMO/kpi/research-and-safety-market-channel-revenue) | $2.0B | quarter to 26 Sep 2026 | up 9.1% |
| [Pharma services revenue](https://aapwire.com/stocks/TMO/kpi/pharma-services-revenue) | $2.0B | quarter to 26 Sep 2026 | up 17.8% |
| [Biosciences revenue](https://aapwire.com/stocks/TMO/kpi/biosciences-revenue) | $1.0B | quarter to 26 Sep 2026 | up 0.2% |
| [BioProduction revenue](https://aapwire.com/stocks/TMO/kpi/bioproduction-revenue) | $896.0M | quarter to 26 Sep 2026 | up 9.7% |
| [Chromatography and mass spectrometry revenue](https://aapwire.com/stocks/TMO/kpi/chromatography-and-mass-spectrometry-revenue) | $859.0M | quarter to 26 Sep 2026 | up 2.1% |
| [Electron microscopy revenue](https://aapwire.com/stocks/TMO/kpi/electron-microscopy-revenue) | $827.0M | quarter to 26 Sep 2026 | up 13.0% |
| [Genetic sciences revenue](https://aapwire.com/stocks/TMO/kpi/genetic-sciences-revenue) | $702.0M | quarter to 26 Sep 2026 | down 2.5% |
| [Laboratory products revenue](https://aapwire.com/stocks/TMO/kpi/laboratory-products-revenue) | $603.0M | quarter to 26 Sep 2026 | up 1.5% |
| [Healthcare market channel revenue](https://aapwire.com/stocks/TMO/kpi/healthcare-market-channel-revenue) | $454.0M | quarter to 26 Sep 2026 | up 2.3% |
| [Chemical analysis revenue](https://aapwire.com/stocks/TMO/kpi/chemical-analysis-revenue) | $316.0M | quarter to 26 Sep 2026 | down 1.2% |
| [Clinical diagnostics revenue](https://aapwire.com/stocks/TMO/kpi/clinical-diagnostics-revenue) | $269.0M | quarter to 26 Sep 2026 | down 4.9% |
| [ImmunoDiagnostics revenue](https://aapwire.com/stocks/TMO/kpi/immunodiagnostics-revenue) | $232.0M | quarter to 26 Sep 2026 | up 0.9% |
| [Transplant diagnostics revenue](https://aapwire.com/stocks/TMO/kpi/transplant-diagnostics-revenue) | $131.0M | quarter to 26 Sep 2026 | up 4.8% |
| [Microbiology revenue](https://aapwire.com/stocks/TMO/kpi/microbiology-revenue) | $70.0M | quarter to 26 Sep 2026 | down 56.8% |
| [Laboratory Products and Biopharma Services revenue](https://aapwire.com/stocks/TMO/kpi/laboratory-products-and-biopharma-services-revenue) | $6.9B | quarter to 26 Sep 2026 | up 15.0% |
| [Life Sciences Solutions revenue](https://aapwire.com/stocks/TMO/kpi/life-sciences-solutions-revenue) | $2.7B | quarter to 26 Sep 2026 | up 5.1% |
| [Analytical Instruments revenue](https://aapwire.com/stocks/TMO/kpi/analytical-instruments-revenue) | $2.0B | quarter to 26 Sep 2026 | up 5.8% |
| [Specialty Diagnostics revenue](https://aapwire.com/stocks/TMO/kpi/specialty-diagnostics-revenue) | $1.1B | quarter to 26 Sep 2026 | down 6.5% |
| [North America revenue](https://aapwire.com/stocks/TMO/kpi/north-america-revenue) | $6.3B | quarter to 26 Sep 2026 | up 10.1% |
| [Europe revenue](https://aapwire.com/stocks/TMO/kpi/europe-revenue) | $3.2B | quarter to 26 Sep 2026 | up 6.5% |
| [Asia-Pacific revenue](https://aapwire.com/stocks/TMO/kpi/asia-pacific-revenue) | $2.2B | quarter to 26 Sep 2026 | up 11.3% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
